Rachel Ellingson - St Jude Vice President - Corporate Relations

Summary

President

Ms. Rachel H. Ellingson is Vice President Corporationrationrate Relations of St. Jude Medical Inc since 2012.

Age	44
Tenure	12 years
Phone	651 756-3301
Web	www.sjm.com

Ellingson joined St. Jude Medical in November 2010 through the acquisition of AGA Medical where she served as Vice President, Business Development and Investor Relations. Prior to joining St. Jude Medical, she spent 15 years in investment banking, most recently as a Managing Director with the medical device team at Banc of America Securities . In February 2011, Ms. Ellingson was named Senior Director, Corporationrationrationrate Strategy and Planning. In October 2011, Ms. Ellingson was promoted to Vice President, Corporationrationrationrate Communications and Investor Relations for St. Jude Medical, and in August 2012, she was promoted to Vice President, Corporationrationrationrate Relations. In July 2014, Ms. Ellingson role was expanded and she was named Vice President, Global Communications where she now oversees internal and external marketing communications, investor relations, U.S. government affairs and corporate giving programs.

Rachel Ellingson Latest Insider Activity

Tracking and analyzing the buying and selling activities of Rachel Ellingson against St Jude stock is an integral part of due diligence when investing in St Jude. Rachel Ellingson insider activity provides valuable insight into whether St Jude is net buyers or sellers over its current business cycle. Note, St Jude insiders must abide by specific rules, including filing SEC forms every time they buy or sell St Jude'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Rachel Ellingson over a month ago

Acquisition by Rachel Ellingson of 4697 shares of Zimmer Biomet subject to Rule 16b-3

St Jude Management Efficiency

St Jude's management efficiency ratios could be used to measure how well St Jude manages its routine affairs as well as how well it operates its assets and liabilities.

Compare St Jude to Peers

The company has 6.39 B in debt with debt to equity (D/E) ratio of 1.29, which is OK given its current industry classification. St Jude Medical has a current ratio of 1.89, which is typical for the industry and considered as normal. Debt can assist St Jude until it has trouble settling it off, either with new capital or with free cash flow. So, St Jude's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like St Jude Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for STJ to invest in growth at high rates of return. When we think about St Jude's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			PRESIDENT Age
	Laura Campbell	Noble plc	51
	Troy Anderson	Universal Technical Institute	56
	Eric Severson	Universal Technical Institute	60
	Scott Marks	Noble plc	58
	Robert Eifler	Noble plc	44
	Lori Smith	Universal Technical Institute	57
	David Chung	51Talk Online Education	N/A
	Eugene Putnam	Universal Technical Institute	54
	Adam Peakes	Noble plc	44
	Thomas Sloan	Noble plc	50
	William Turcotte	Noble plc	60
	Stephen Butz	Noble plc	46
	Annette Meier	Superior Drilling Products	61
	Simon Johnson	Noble plc	46
	Richard Barker	Noble plc	42
	Piper Jameson	Universal Technical Institute	53
	Jerome Grant	Universal Technical Institute	61
	Bryce Peterson	Universal Technical Institute	37
	Rhonda Turner	Universal Technical Institute	42
	Alain Laplante	Orbit Garant Drilling	N/A
	Sherrell Smith	Universal Technical Institute	61

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. St Jude Medical (STJ) is traded on New York Stock Exchange in USA and employs 18,000 people.

Management Performance

	Return On Equity	0.23
	Return On Asset	0.0011

St Jude Medical Leadership Team

Elected by the shareholders, the St Jude's board of directors comprises two types of representatives: St Jude inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STJ. The board's role is to monitor St Jude's management team and ensure that shareholders' interests are well served. St Jude's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, St Jude's outside directors are responsible for providing unbiased perspectives on the board's policies.

	David Lamb, Managing Director, Executive Director
	Baroness Wheatcroft, Non-Executive Independent Director
	Ian Gascoigne, Managing Director, Executive Director
	John Heinmiller, Executive VP
	Tony Dunk, Director - Investor Relations
	Denis Gestin, President of International Division
	Craig Gentle, CFO
	Stephan Widensohler, Independent Director
	Donald Zurbay, CFO and VP of Fin.
	Lisa Andrade, Chief Marketing Officer
	Wendy Yarno, Independent Director
	Iain Cornish, Senior Independent Non-Executive Director
	Richard Devenuti, Independent Director
	Sarah Bates, Non-Executive Chairman of the Board
	Jeffrey Dallager, Vice President Corporate Controller
	Joel Becker, President - Americas Division
	Stuart Essig, Independent Director
	Andrew Croft, CFO, Executive Director
	Barbara Hill, Independent Director
	David Bellamy, Chief Executive, Executive Director
	Roger Yates, Independent Non-Executive Director
	John Brown, Independent Presiding Director
	Daniel Starks, Executive Chairman
	Eric Fain, Group President - St. Jude Medical
	Elizabeth Kelly, Company Secretary
	Rachel Ellingson, Vice President - Corporate Relations
	Mark Carlson, Vice President - Global Clinical Affairs, Chief Medical Officer
	Paul Bae, Chief Marketing Officer, Vice President - Global Human Resources
	Michael Rousseau, CEO and President COO and Director
	Mark Murphy, CIO and VP of Information Technology
	Scott Thome, Vice President - Global Operations and Supply Chain
	Michael Rocca, Independent Director
	Simon Jeffreys, Independent Non-Executive Director
	Jeff Fecho, Vice President - Global Quality
	Jason Zellers, Vice President General Counsel, Corporate Secretary
	J Weigelt, Director - Investor Relations
	David Dvorak, Director
	Robert Gardner, Director of Investment Management
	Stefan Widensohler, Independent Director

STJ Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is St Jude a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	0.23
	Return On Asset	0.0011
	Profit Margin	0 %
	Operating Margin	21.11 %
	Current Valuation	19.98 B
	Shares Outstanding	282.2 M
	Shares Owned By Insiders	2.44 %
	Shares Owned By Institutions	86.30 %
	Number Of Shares Shorted	8.18 M
	Price To Earning	35.37 X

Currently Active Assets on Macroaxis

BAC	Bank of America
DD	Dupont De Nemours
F	Ford Motor
WD	Walker Dunlop
GOOG	Alphabet Inc Class C

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in STJ Stock

If you are still planning to invest in St Jude Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the St Jude's history and understand the potential risks before investing.

	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC